It is made available under a CC-BY-NC 4.0 International license.

Predicting vaccine effectiveness in Mpox

-
- 3 Authors: Matthew T. Berry¹, Shanchita R. Khan¹, Timothy E. Schlub^{1,2}, Adriana
- 4 Notaras¹, Mohana Kunasekaran¹, Andrew E. Grulich¹, C Raina MacIntyre^{1,3},
- 5 Miles P. Davenport¹, David S. Khoury¹
- Affiliations:
- 1. Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
- 2. Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- 11 3. College of Public Service & Community Solutions, and College of Health Solutions, Arizona State University, Tempe, United States.
-
-
- **# corresponding authors:**
- David Khoury
- Kirby Institute, UNSW Sydney
- Kensington, NSW 2052
- dkhoury@kirby.unsw.edu.au
-
- Miles Davenport
- Kirby Institute, UNSW Sydney
- Kensington, NSW 2052
- m.davenport@unsw.edu.au
-
-

Abstract:

 The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent Mpox during the 2022 global outbreak. This vaccine was initially approved for Mpox based on its reported immunogenicity and effectiveness in animal models, rather than evidence of clinical efficacy. However no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against Mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. Although further work is required to validate this correlate, this study provides the first evidence-based approach for using antibody measurements to predict the effectiveness of Mpox vaccination.

 Mpox virus (formerly Monkeypox) is a zoonotic virus endemic in West Africa, with 43 significant outbreaks in 1980-1986 and in 1997-1998¹, resulting in over 20,000 total recorded cases. Prior to 2017, these outbreaks were typically small and initiated by zoonotic 45 transmission followed by self-terminating human-to-human chains of transmission². However, since 2017, there has been a resurgence of Mpox in Nigeria, Democratic Republic of the Congo (DRC) and other parts of Africa, attributed to waning immunity from smallpox 48 vaccines and accumulation of cohorts that have never been vaccinated against smallpox³. In 2022, a global outbreak of Mpox resulted in 91000+ confirmed cases in 115 countries and established chains of human-human transmission leading to a renewed focus on vaccination 51 as a preventative measure for M pox⁴. Although there is no Mpox-specific vaccine, first generation smallpox vaccination was observed to protect individuals against Mpox infection during the 1980-1986 Mpox outbreak 54 in the DRC (then Zaire)⁵⁻⁸, with an estimated vaccine effectiveness of approximately 85% ⁵, 55 and this has also been observed in similar subsequent studies⁹⁻¹¹. However, the live- replicating vaccinia vaccines (first and second-generation) have significant risks of serious 57 vaccine adverse events¹², which led to the development of the third-generation Modified Vaccinia Ankara live-attenuated (replication deficient) vaccine (MVA-BN). Prior to the 2022 Mpox outbreak, MVA-BN was approved by the FDA for use as a Smallpox and Mpox 60 vaccine (two doses of 1×10^8 TCID via subcutaneous injection). Given the challenge of directly assessing the efficacy of this vaccine in an RCT, regulatory approval was based on demonstrated non-inferior immunogenicity profile and improved safety compared to the second-generation ACAM2000 vaccine¹³. In particular, comparing vaccinia neutralizing antibody titers induced by vaccination of MVA-BN and ACAM2000, it was deemed "reasonable to expect that this regimen of the vaccine is effective in smallpox vaccinia-naïve 66 as well as in smallpox vaccine experienced individuals"¹³. This was supported by studies in nonhuman primates implicating antibodies directly in mediating protection against lethal 68 Mpox challenge¹⁴. Analysis of case data during the 2022 global outbreak indicates that the MVA-BN vaccine is

70 effective for prevention of $Mpox¹⁵⁻²⁰$, and affirms the decisions to use these vaccines during the outbreaks. However, important questions remain to be addressed. Firstly, how does MVA-BN effectiveness compare with the protection conferred by the live replicating smallpox vaccines, and how many doses are required? Further, is the protection from MVA- BN vaccination expected to be durable, and will further booster doses be required to confer durable protection against Mpox and protect individuals in potential future outbreaks?

- Here we address these questions by aggregating the available data on the effectiveness of
- different vaccinia-based vaccination regimes in protection against Mpox. We compare
- protection from first generation smallpox vaccines with the protection conferred by one or
- two doses of the MVA-BN vaccine. Further, given the assumed role of antibodies, we
- aggregate data on vaccinia-specific ELISA endpoint titers (here after referred to as vaccinia-
- binding titers) after MVA-BN vaccination (which have been shown to correlate with
- 82 neutralizing antibody titers to Mpox after vaccinia vaccination²¹), and study the relationship
- between antibody levels and effectiveness. Finally, we analyze the kinetics of antibody decay
- over time to predict the duration of protection afforded by 1, 2 or 3 doses of vaccination. This
- work offers a data-driven approach to support public health decision making on Mpox
- vaccination and boosting campaigns.

It is made available under a CC-BY-NC 4.0 International license.

Results

Search results of vaccine effectiveness and immunogenicity studies

- Our search identified 14 studies of vaccine effectiveness against Mpox that met the inclusion
- criteria (fig. S1). These studies included analysis of secondary contacts (n=5), case-coverage
- 92 studies ($n=5$), a cohort study ($n=1$), and case-control studies ($n=3$) (Table S1). Of these
- studies, seven reported vaccine effectiveness from first generation smallpox vaccination,
- three determined effectiveness after one-dose of MVA-BN only, and four studies included
- 95 protection from both one and two doses of MVA-BN. One study by Payne et al.²² was
- excluded, because a more recent report by the same authors was identified that contained
- 97 more data¹⁷. Further, another 2 studies^{5,8} were excluded as they were all performed using
- similar secondary contact data from the Democratic Republic of Congo during the 1980-1986
- outbreaks and thus we used only the study providing the most detailed disaggregation
- 100 temporally and by age⁷.
- Our systematic search for immunogenicity data yielded 27 clinical trials that reported on
- antibody responses after MVA-BN vaccination (fig. S2). A subset of 12 trials were identified
- that reported vaccinia-binding titers in healthy individuals²³⁻³⁵, and one further trial was
- 104 published only on the clinicaltrials.gov database³⁶ (Table S2). These trials used similar
- methodologies to assess vaccinia-binding, allowing comparison of immunogenicity between
- trials. Two studies contained data on all three relevant groups (historic smallpox vaccination,
- 1 dose MVA-BN and 2 dose MVA-BN vaccination), and eight studies contained data for
- both the MVA-BN 1-dose and 2-dose groups.
-

Vaccine effectiveness against Mpox

Using the studies identified by our systematic search, we performed a meta-analysis to

- estimate an aggregate vaccine effectiveness (VE). In this analysis, we stratified data by
- vaccine type (i.e. historic first-generation, or recent 1-dose or 2-dose MVA-BN vaccination),
- and a hierarchical model structure was used to account for study heterogeneity (fig. 1a and
- Table S3). Aggregating the available data, we used a Bayesian hierarchical model to obtain
- best-estimates of the effectiveness for first-generation vaccines (76.5%, CI:59-87%), one
- dose of MVA-BN (74.2%, CI:57-84%) and two doses of MVA-BN (82.2% CI:69-89%). We
- observed that one dose of MVA-BN provided lower effectiveness than historic vaccination,
- whilst two doses provided higher effectiveness, though neither of these results were
- significant (OR = 1.09, CI:0.55-2.47, OR=0.75, CI: 0.37-1.73, respectively). Importantly, we

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.11.23.23298850;](https://doi.org/10.1101/2023.11.23.23298850) this version posted November 24, 2023. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

- had limited power to detect such a difference and this is reflected by the large credible
- intervals. Despite the variation in reported VE across different studies (ranging from 35.8-
- 86.4% for 1 dose and 66-89.5% for 2 doses), we observe a significant benefit of two dose
- 124 vaccination over one dose vaccination (OR=0.69 (CI: 0.54-0.86)) evident because four
- studies compared VE after 1 and 2 doses, and all four showed a trend for higher VE after 2
- doses (fig. 1b).
-
-
-
-

 Figure 1: The estimated effectiveness of different Mpox vaccine regimens. (A) The estimated 134 effectiveness of first generation (1st Gen) vaccines (n= 5), a single dose of MVA-BN (n = 6), and two doses of MVA-BN (n=4) are shown. The estimated effectiveness and 95% credible intervals (shapes and error bars) in each study along with the combined estimates for effectiveness (black circle) for different regimes are shown. Where two regimes were compared in the same study, the effectiveness of the two regimes is joined by a line. (B) The additional protection (odds ratio) provided by a two- dose regime compared to a one dose regime. The combined estimates (black) are the medians of the posterior distribution (circle) with the 95% credible intervals (error bars).

It is made available under a CC-BY-NC 4.0 International license. perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.11.23.23298850;](https://doi.org/10.1101/2023.11.23.23298850) this version posted November 24, 2023. The copyright holder for this

Vaccinia-binding titers in vaccinated individuals

- To investigate the immunogenicity of different vaccination strategies, we aggregated data on the geometric mean vaccinia-binding titers (GMT) reported 4 weeks after 1 dose MVA-BN and 2 weeks after 2 dose MVA-BN. Our analysis aggregated data from studies that used slightly different ELISA assay protocols to estimate antibody titers (Table S2). We fit a Bayesian model with covariates for vaccine formulation and ELISA assay used, and a hierarchical structure to account for interstudy variability (see Methods, Table S4). Interestingly, we found no significant effect of the ELISA assay used to measure the GMT (fig. S3a), but the formulation of the vaccine had a significant effect on the antibody titer (freeze dried formulation provided higher titers than liquid frozen, p<0.001) (fig. S3b). Since the liquid frozen formulation was the formulation deployed in the effectiveness studies, we focus our analysis on this formulation. After accounting for all study and formulation differences, we found that the GMT induced by one dose of liquid frozen MVA-BN provides a higher antibody level than that observed in individuals who received a first-generation 157 vaccine historically (GMT = 87.2 (CI: 66.9-115) vs 58.7 (CI: 41.4-82.2), fold difference 1.49 (CI:1.16-1.92)), and a second dose of liquid frozen MVA-BN provided a significant boost over a single dose (8.42-fold (CI: 7.79-9.10) increase, fig. 2).
-

Figure 2: Comparison of the reported geometric mean vaccinia-binding titers induced by

- 163 vaccination with MVA-BN and historic first-generation vaccines. The GMTs from the freeze-
- dried MVA-BN formulation (light-color) are significantly higher than the liquid frozen
- formulation (dark-color) (1.32-fold, CI:1.20-1.48, p<0.001). Horizontal lines indicate the

combined estimate (median of the posterior distribution) for each vaccination and

formulation (dashed lines are the 95% credible intervals).

Estimating a quantitative relationship between vaccinia-binding titers and vaccine

effectiveness

 Antibody titers are thought to be a surrogate of vaccine effectiveness for both smallpox and 173 Mpox infection^{14,37}, and were used to support the regulatory approval of MVA-BN¹³. This is supported by animal studies showing an important role of antibodies in protection from Mpox¹⁴. Thus, we sought to investigate the relationship between vaccinia-binding antibody titer and effectiveness by combining the available immunogenicity data and effectiveness data. No study found in our searches contained both effectiveness data and immunogenicity data from the same cohort. Therefore, we matched the immunogenicity data to the corresponding vaccine effectiveness data by vaccine regimen. That is, 1-dose MVA-BN vaccination (n=10 immunogenicity, and n=6 effectiveness studies, respectively), 2-dose MVA-BN vaccination (n=11, and n=4) and historic first-generation smallpox vaccination (n=3, and n=5). Although we have very limited data to assess a correlation (i.e. only three vaccine groups across 14 effectiveness and 13 immunogenicity studies), fitting a logistic relationship between antibody titers in these groups and effectiveness (following the 185 approach used in COVID-19^{38,39} (fig. 3), we found evidence of a significant positive association between antibody titers and effectiveness (OR: 0.62 (CI 0.47-0.82) for each 10- fold change in vaccinia-binding, p<0.001) (Table S5). This supports the use of vaccinia- binding titers as a correlate of vaccinia-based vaccine effectiveness. Further, this model provides a quantitative method to predict vaccine effectiveness (along with credible intervals) associated with different antibody titers and waning immunity.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.11.23.23298850;](https://doi.org/10.1101/2023.11.23.23298850) this version posted November 24, 2023. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

 Figure 3: Relationship between vaccine effectiveness and the vaccinia-binding GMT. The global estimates of vaccine effectiveness and vaccinia-binding titers across different vaccination regimes are shown with colored contour lines. The contours represent the lines of equal probability of the normalized joint-posterior density (combining posterior densities from the vaccine immunogenicity and effectiveness analyses, i.e. fig. 1 and 2, respectively). The association between antibody titers and effectiveness (solid black line) is fitted using all of the underlying data (accounting for the interstudy heterogeneity using a hierarchical model structure) (Table S5). The solid black line indicates the best estimate (median of posterior), and shaded region show the 95% credible intervals of the predicted effectiveness at different GMTs.

Boosting and waning of antibody titers with MVA-BN vaccination

 A major question regarding Mpox control is how to optimize vaccine distribution and dosing intervals in the context of a potential future outbreak. Estimates of both the durability of protection and of the effects of the interval between first and second dose of MVA-BN would be informative in guiding policy for future responses. The immunogenicity studies we identified included a subset of studies that reported long-term follow up of antibody titers after MVA-BN vaccination (up to 24 months), as well as the effects of different timing of a 210 second MVA-BN dose^{24,25,27-36}. To explore the effect of dose timing on the peak and durability of antibody responses, we fitted a two-phase antibody decay model to the available vaccinia-titers over time for different vaccination regimens (fig. 4a). From this analysis we 213 firstly noted, consistent with other vaccines⁴⁰, increased spacing between MVA-BN vaccine doses led to a higher peak antibody response (measured at 14 days post-last dose or 28 days post-initial dose, whichever is later) (fig. 4b). For example, delaying the timing of the second

dose from 7 days to 28 days led to a 4.2-fold (CI: 2.1-8.8) higher antibody titer. Delay from

28 days to 730 days led to a 3.2-fold (CI:2.6-3.8) higher titer. Interestingly, the peak antibody

- titer after a second dose of MVA-BN at 730 days was very similar to the peak titer of a third
- dose of MVA-BN at 730 days (after an initial 28 day-spaced two-dose regime) (GMR 1.03,

CI:0.82-1.31).

 Regarding decay, we observed a fast initial decay and slow long-term decay of antibody titers (i.e. model comparison indicates that a two-phase decay model is superior to a single-phase decay, Table S7), and the estimated half-life of the fast-decaying and slow-decaying antibody titer was 20.7 (CI:18.2-24.0) days and 1721 (CI:971-6459) days, respectively. The estimated

decay rates of the fast and slow-decaying antibodies were not different between the regimes

(Table S7). However, the initial antibody titer and proportion of slow-decaying (long-lived)

antibodies varied between groups (fig. 4 and S4, discussed below). Interestingly, the

- proportion of long-lived antibodies increased in individuals with a 730-day spacing between
- 229 first and second dose, when compared with the standard two dose schedule (fig. S4 & Table

S8). Thus, when we consider the predicted antibody titers one year after boosting, delaying

- the second dose to 730 days provides a 17.0 (CI: 13.5-21.2) fold higher titer compared to
- standard boosting at 28 days (fig. 4c and Table S8). Interestingly, whether vaccination at 730

days was given as a second booster, or as a third booster (after a second at 28 days), the

234 durability of the response was similar (GMR 1 year after peak of 3 doses to 2 doses: 1.2

(CI:0.89-1.63)).

 Of note, we estimate that antibody titers after 2 doses of MVA-BN vaccination (with 28-day interval) remain above or equal to the peak GMT of one dose for 81 days (CI:72-93) and above historically vaccinated cohorts for 102 days (CI: 74-173). By delaying the second dose to two years, antibody titers remain above the one-dose peak for 13.2 years (CI:7.5-48.3

- years). Together these results suggest that a delayed booster or third dose provides higher and
- more durable antibody titers.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.11.23.23298850;](https://doi.org/10.1101/2023.11.23.23298850) this version posted November 24, 2023. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

 immunogenicity trials as fitted using a two-phase decay model. The estimated GMT (solid lines) and 95% credible intervals (shaded) are shown over the two-year period for which immunogenicity data

 was measured in the one and two dose schedules. (B) The effect of delayed dosing. The GMT at the approximate peak (2 weeks after the final dose or 28 days after the first dose, whichever is later) is

shown for different MVA-BN vaccination regimes. (C) The predicted GMT one-year post-

vaccination, accounting for the early fast-decay and the late slow-decay of antibodies (Table S8).

- Predicted GMTs for regimens without a datapoint later than 5 months post-vaccination are faded. (D)
- The predicted vaccine effectiveness over a 10-year period for the different vaccination schedules. The

grey region highlights the prediction extrapolated beyond the available time course of

- immunogenicity data. The three-dose schedule involves vaccination on day 28 and 2 years after the 256 initial dose $(3rd$ dose delivered on day 730).
-
-

Predicting vaccine effectiveness

- Using the decay kinetics of antibody titers estimated above (fig. 4a), and the logistic
- relationship between antibody titers and vaccine effectiveness (fig. 3), we can predict the
- duration of vaccine protection under different vaccine schedules (fig. 4d). Our analysis
- predicts vaccination with one dose of MVA-BN will have an effectiveness of 66.6%
- (CI:51.87-77.7) at 2 years post vaccination (note that this VE estimate is an extrapolation
- below the range of data in fig. 3). A two-dose regimen on a 4-week schedule is anticipated to
- still provide 73.2% (CI:61.9-81.4) effectiveness from Mpox infection at 2 years.
- Extrapolating antibody decay beyond the available time series (shaded region in fig. 4d), we
- also predict the level of long-term effectiveness from 1 and 2-dose MVA-BN vaccination
- (with 28-day spacing) after 10 years will be 61.3% (CI: 42.6-75.4) and 68.4% (CI:53.0-78.9),
- respectively. This is based on the conservative assumption that antibody decay continues at
- the same rate over 10 years (although studies of antibody decay after first generation vaccinia
- 272 vaccination suggest the half-life may continue to slow to as long as 99 years³⁷). If the second
- vaccination is delayed to 730 days, then the predicted effectiveness at 10 years post-boost is
- 78.6% (CI:68.7-85.8). Together this analysis predicts long-term protection against Mpox after
- 1, and especially 2 doses of MVA-BN vaccination.

Discussion

 The ongoing spread of Mpox in West and Central Africa, the 2022 global pandemic, and the associated changing epidemiology of Mpox virus highlight the importance of an improved

understanding of Mpox vaccination and immunity. Novel vaccinia-based vaccines were

- 281 anticipated to be as effective against Mpox as historical first-generation smallpox vaccines^{5,7}.
- However, determining the efficacy of novel Mpox vaccines has proved challenging due to the
- difficulties in performing large randomized controlled trials (RCTs). In lieu of RCTs, a

correlate of protection from immunogenicity data can be used in the vaccine development

- process. Neutralizing antibody titers have been proposed as a correlate due to their role in
- 286 protection from a lethal Mpox challenge in animal models¹⁴. Subsequently, neutralizing
- antibodies and animal studies formed the basis for the approval of MVA-BN as a third-
- 288 generation smallpox and Mpox vaccine¹³.

In this work we aggregate the available data to study the relationship between vaccine

- immunogenicity and vaccine protection from Mpox infection. Analysis of the vaccine
- effectiveness data indicates that single dose MVA-BN is non-inferior to historical vaccination
- 292 with first generation smallpox vaccines $(OR = 1.09, (CI: 0.55-2.47))$. These findings support
- the choice to adopt MVA-BN vaccine for control of Mpox given its comparable effectiveness
- 294 to first generation vaccines, and its beneficial safety profile³². Further, our meta-analysis
- finds 2 dose MVA-BN vaccination to be more effective than 1 dose (OR=0.69 (CI: 0.54-

0.86)).

 A validated surrogate marker of Mpox immunity would greatly assist in vaccine development and deployment, and in predicting the longevity of protection and necessity for boosting.

Here we find a weak but significant association between antibody titers and vaccine

effectiveness, albeit with very limited data. The significance of this association is

predominantly influenced by the result that 2 doses of MVA-BN has both higher

effectiveness and higher antibody titers than 1 dose. Caution is required before interpreting

this result as a demonstration of antibody titers as a correlate of protection for vaccinia

vaccines against Mpox, since we have limited data available, a small range in observed

- effectiveness, and large interstudy variation. Our observation, however, supports the existing
- 306 results from animal models that antibodies may be a correlate of protection against $Mppx^{14}$.
- If we assume that antibody titers are indeed a correlate, our model provides confidence limits
- for the long-term effectiveness given the available data. A major challenge during the 2022
- global Mpox outbreak was prioritizing the use of the small pool of existing MVA-BN

It is made available under a CC-BY-NC 4.0 International license.

 vaccines. In particular, it was unclear whether improved overall outcomes would be achieved by, 1) maximizing the number of individuals who could receive a first dose, thus giving them some protection, or 2) focusing on maximizing the number of individuals who could receive the full two dose regimen and ensure they had a sufficient immunological response for protection. Our analysis suggests that 2-doses of the vaccine provide only a slight increase in effectiveness compared to 1-dose (82.2% vs 74.2%). Therefore, in the context of a limited number of available doses, the increase in protection provided by a second dose (to recently vaccinated individuals) is less than the protection that could be obtained by giving a single dose to as many naïve individuals as possible. Assuming a population with equal risk, 1.81- times (CI:1.58-1.93) more cases could be averted by giving a single dose to twice as many individuals rather than a full 2 doses to a smaller group.

Initially administering a single dose to the maximum number of people and delaying a second

dose until there is increased availability of vaccine may provide additional benefits in terms

of the durability of protection. For example, delaying a second dose until 2 years after the

first dose is expected to provide a 3.2-fold higher peak titer and 14.1-fold higher titer at 1

year (compared to a second dose at 28 days) (fig. 4a). Even though delaying a second dose

produces a longer period of lower protection before boosting, protection from a single dose of

MVA-BN is predicted to remain >65% at 2 years (compared to 72% at 2 years for a 2-dose

regime) (fig. 4d). Further work is required to understand the optimal spacing of booster doses

to maximize both short and long-term protection. However, these data predict that

administering single doses initially allows the deployment of the vaccine more rapidly to

more individuals during an emergency, and by delaying the second dose there is a potential

advantage to the long-term durability of protection.

Our analysis includes a significant number of limitations. Firstly, the studies on vaccine

effectiveness show a large amount of study heterogeneity (Table S1). For example, the

estimated vaccine effectiveness after one dose of MVA-BN varies between 35.8% (CI:22.1-

47.1)¹⁶ to 86.4% (CI:83.3-89.0)¹⁷. This is perhaps not surprising, given the effectiveness data

was obtained from observational studies with different study designs and potential

confounders.

A major challenge in using non-randomized studies is appropriate matching of control groups

(in case-control studies) and identification of the at-risk population (in case-coverage

studies). Differences in matching cases to controls significantly affect the reported levels of

343 . protection^{15,16,19}. In addition, large case-coverage studies attribute the reduction in case

It is made available under a CC-BY-NC 4.0 International license.

 numbers to vaccination, but this may not control for confounders such as differences in behavior (which have been associated with a reduction in spread in Italy prior to the commencement of vaccination⁴¹). These confounders may contribute to the substantial heterogeneity in VE observed across studies (fig. 1). We can partially account for unmeasured confounding by using a hierarchical model to account for inter-study variability, but systematic biases that result from unmeasured confounding are unable to be completely excluded. Further, the route and dose of MVA-BN administered varied over time and in different regions. For example, during the 2022 outbreak, following changes in FDA recommendations in the US, 45.9% of individuals received their first dose (and 85.7% received their second 354 dose) via an intradermal (ID) injection of 2×10^7 TCID, instead of the per label 355 recommendation of 1 x 10⁸ TCID administered subcutaneously $(SC)^{42}$. Our analysis of the effectiveness data could not test whether protection was impacted by the method of administration since the effectiveness studies did not disaggregate data by mode of

- 358 administration (SC or ID). However, Panye et al.¹⁷, who tested for a difference in VE
- between individuals who received SC and those who received ID, reported no difference.
-

 Another limitation is that the VE data and immunogenicity data came from independent cohorts and studies. Thus, there is no guarantee that the populations are well matched. Specifically, there is a significant mismatch in the demographics of the vaccine effectiveness studies and the immunogenicity trials. For example, the population considered in the US study for vaccine effectiveness¹⁷ considered only men (sex assigned at birth or gender identity) aged between 18-49. On the other hand, the clinical trials of antibody responses post vaccination were all tested on populations of both men and women and featured slightly different age ranges. Further, even though the majority (85.7%) of individuals in the US received their second dose of MVA-BN via intradermal administration⁴², the majority of the available immunogenicity data was from individuals with SC administration (creating a potential mismatch in the effectiveness data and immunogenicity data). Fortunately, immunogenicity data suggests similar antibody titers between the two modes of 373 administration²⁴. An additional difference between immunogenicity and effectiveness studies was in the time between vaccination and serum sampling and effectiveness assessment. Whereas immunogenicity was assessed at 4 or 2 weeks after first or second vaccination respectively, the time from vaccination to infection is only reported in one study (Wolff Sagy et al.¹⁸, where 3 of 5 infections occur in week 3, and the other two infections occur in week

It is made available under a CC-BY-NC 4.0 International license.

 6). A mismatch also exists in comparing historic first-generation vaccination. The effectiveness data are from studies in the Democratic Republic of Congo in the 1980s to 2010s, whereas the immunogenicity data are from individuals in the United States (who in most cases were vaccinated >40 years earlier). As well as differences in the viral clades between these outbreaks^{43,44}, timing of previous vaccination in the historic vaccine effectiveness studies is not recorded and may not be well matched to the immunogenicity 384 studies. Evidence of a very slow long-term decay of antibodies $37,45-47$ suggests that time- since-vaccination may not be critical in comparing these groups many years after vaccination. However, it was not possible to match for age of vaccination, health status, or other demographic variables and their effects on immunogenicity and protection are unknown. Previous work has shown that vaccination in childhood confers longer protection than 389 vaccination in adulthood⁴⁸. Further investigation of the risk of breakthrough infection in historically smallpox vaccinated cohorts are required to confirm this assumption and improve 391 our understanding of the duration of Mpox immunity from vaccinia vaccines⁴⁹.

Finally, it is important to emphasize that we identified a relationship between vaccinia-

binding titers and vaccine protection. Although vaccinia-binding titers are correlated with in

395 vitro neutralizing antibody titers to $Mpox²¹$, they are likely not an optimal measure of

- antibody effectiveness against Mpox. Further work is necessary to compare different measures of immunogenicity to better standardize assays to define a correlate of protection
- for Mpox.

 This study brings together the limited and heterogenous data available on immunogenicity and protection from Mpox after MVA-BN vaccination. We report non-inferiority of MVA- BN against Mpox compared to historic first-generation smallpox vaccination and define a candidate surrogate of vaccine effectiveness based on vaccina-binding titers. We then use that surrogate to predict the duration of vaccine effectiveness. We predict that, since long-term vaccinia specific titers remain high, MVA-BN vaccine effectiveness will remain >60% for up to 10 years, even after a single dose. This prediction of durable immune responses is consistent with reports of first and second generation vaccines against smallpox, where detectable immune responses and protection (particularly from severe infection) are thought 409 to persist for over 20 years⁵⁰⁻⁵² (reviewed in Kunasekaran et al⁴⁸). Our approach allows the prediction of vaccine effectiveness based on the existing available evidence, but also indicates the urgent need for further studies of MVA-BN immunogenicity and protection.

- The development of a standardized assay for Mpox antibody binding or neutralization and a
- serological standard for comparison are important priorities. In the absence of this,
- comparison between studies by normalizing antibody levels to those induced by (for
- 415 example) 1 dose MVA-BN vaccination (similar to methods used in COVID-1938,39) is
- possible but not ideal. In addition, public health plans for a potential future Mpox outbreak
- need to be developed, ideally informed by the best available evidence for vaccine
- effectiveness.

It is made available under a CC-BY-NC 4.0 International license.

References

It is made available under a CC-BY-NC 4.0 International license.

It is made available under a CC-BY-NC 4.0 International license.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.11.23.23298850;](https://doi.org/10.1101/2023.11.23.23298850) this version posted November 24, 2023. The copyright holder for this

It is made available under a CC-BY-NC 4.0 International license.

- 52 Nishiura, H., Schwehm, M. & Eichner, M. Still protected against smallpox? Estimation of the duration of vaccine-induced immunity against smallpox. *Epidemiology* **17**, 576-581 (2006). <https://doi.org:10.1097/01.ede.0000229196.41862.c2>
- 53 Bunge, E. M. *et al.* The changing epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS Negl Trop Dis* **16**, e0010141 (2022). <https://doi.org:10.1371/journal.pntd.0010141>
- 54 WebPlotDigitizer v. 4.6 (2022). <https://automeris.io/WebPlotDigitizer>
- 55 RStan: The R interface to Stan v. 2.26.23 (2023). <https://mc-stan.org/>
- 578 56 Stan Modeling Language Users Guide and Reference Manual v. 2.23 (2023). [https://mc-](https://mc-stan.org/)[stan.org](https://mc-stan.org/)
- 57 Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine
- effectiveness. *Vaccine* **31**, 2165-2168 (2013).<https://doi.org:10.1016/j.vaccine.2013.02.053>

Methods

Search strategy

We aimed to aggregate the available data that reported on both vaccine protection against

Mpox infection and vaccine immunogenicity in order to understand the relationship between

immunogenicity and protection. For vaccine protection studies, we used a recently published

588 systematic review⁵³ and extended this here. To obtain matching immunogenicity data, we

performed a systematic search of ClinicalTrials.gov for all studies of MVA-BN

immunogenicity.

Search Strategy for vaccine effectiveness data

Our search strategy for identifying studies of vaccine effectiveness was based upon the search

strategy in the systematic review by Bunge et al.⁵³. This systematic review identified articles

relating to Mpox prior to $7th$ September 2020. We extend this by conducting a systematic

search from that date up to $10th$ July 2023 using the same search strategy, with the following modifications:

598 - included Mpox[tiab] to account for the recent name change,

 - we added the search terms AND (Vaccine[tiab] OR Vaccination[tiab]), since our search results are only targeted towards vaccine effectiveness (rather than all studies reporting on Mpox).

 For inclusion in our analysis, a study needed to report Mpox incidence data by vaccination status along with an estimate, or the data required for estimating, the at-risk population for observational studies, or a control group in case-control studies.

Search strategy for Immunogenicity

 Since vaccinia-binding IgG antibody titers after MVA-BN vaccination have been shown to be 608 highly correlated with neutralizing antibodies against vaccinia and Mpox viruses²¹, and

because of the limited data on *in vitro* neutralization of Mpox virus, we focused our search of

immunogenicity data on vaccinia-binding titers. The immunogenicity data was obtained by

searching through the clinicaltrials.gov database for clinical trials using the MVA-BN

vaccine. We searched for intervention trials with 'MVA' as the intervention with condition,

'smallpox OR Monkeypox OR Variola'. We only considered studies that had been

completed. For inclusion in our analysis, the intervention had to be MVA-BN (different types

of MVA vaccines have been tested in the past but are not used for immunization against

 Mpox). Our analysis only considers healthy individuals. Therefore, at least one arm in the trial had to include a healthy population for the trial to be included in our analysis.

Data extraction

 For data on vaccine effectiveness, we extracted the case/control incidence (number of events) data reported in each study disaggregated by timepoint, age or region where possible. For immunogenicity data, we contacted the sponsor by e-mail to request access to the de- identified individual-level data presented in the published work. This request was denied (27 March 2023). Therefore, we extracted summary data (Geometric Mean Titer (GMT) and 625 confidence intervals (CI)) from tables (where available) or figures using WebPlotDigitiser⁵⁴. Where data was extracted from an image, two individuals (MB, SRK) extracted the data independently with the geometric mean of the two extracted values used and we confirmed that discrepancies between extracted values were always less than 1%.

Statistical analysis

All meta-analyses and meta-regression were performed using a hierarchical Bayesian data

- 632 analysis framework in RStan^{55,56} using the default HMC sampler. This included global
- estimates of mean effectiveness, and antibody titers after vaccination, estimates of the decay
- kinetics of antibody titers, and fitting the relationship between antibody titers and
- effectiveness. Hierarchical model structures were used to account for inter-study variability in
- all analyses, and unless otherwise stated all reported estimates are posterior medians, along
- with 95% credibility intervals (CI). To perform statistical tests of whether a parameter (or
- 638 difference in parameters), g, was significantly different to zero we defined a p-value, $p =$
- 639 2 × min ($P(q > 0)$, $P(q < 0)$), which was calculated from the posterior distributions of
- 640 estimated parameters. Significance was defined as $p<0.05$.
-

Estimating vaccine effectiveness

 In our meta-analysis of vaccine effectiveness, we implement a modified version of the 644 Bayesian binomial approach $27,28$ to fit the raw event data from each study. The binomial model assumes individuals in a given population, N, have an unknown probability of 646 infection, r. Therefore, the number of infections, n, follow a binomial distribution, $p(n|r) =$ 647 Bin (r, N) , with posterior distribution,

$$
p(r \mid n) = \frac{p(n \mid r)p(r)}{p(n)}.
$$

It is made available under a CC-BY-NC 4.0 International license.

- 649 We use an un-informative prior on the probability of infection, i.e. $p(r) \sim Beta(1,1)$. An
- 650 equivalent model is used for the risk of infection after vaccination, r_v , with the vaccine
- 651 effectiveness $E = 1 OR$, where OR is the odds ratio (of the risk of infection between
- 652 unvaccinated and vaccinated individuals). Under the assumption of a rare disease ($r \ll 1$), the
- 653 odds ratio, risk ratio and hazard ratio converge.
- 654 For all studies, we used the most temporally disaggregated data available (Table S1). This
- 655 allows us to better account for changes in incidence and vaccine coverage over the outbreak.
- 656 We also used data disaggregated by demographic factors, such as age, where available.
- 657 Groups or timepoints in which no cases were reported in both control and vaccinated
- 658 populations were excluded from the analysis. We assumed that the baseline risk of infection
- 659 in unvaccinated individuals could differ for temporally or spatially disaggregated groups
- 660 from the same study, but we assumed the vaccine effectiveness was constant. That is, for a
- 661 given study, s, we had pairs of data $(n_{i,v,s}, N_{i,v,s})$, where, $n_{i,v,s}$ is the number of infections and
- δ 662 $N_{i,v,s}$ the total individuals of the disaggregation group *i*, with vaccine *v*, in study *s*. We
- 663 estimate a different baseline risk in unvaccinated individuals ($v = 0$), $r_{i,0,s}$, for disaggregation 664 group *i*, and a fixed vaccine effectiveness E_v . The risk of infection after vaccination ($v \neq 0$) 665 is then given by,
- 666 $\logit(r_{i,p,s}) = \logit(r_{i,0,s}) + \log(1 E_p) + S_s$ 1
- 667 where S_s is the random effect on the risk reduction from vaccination (on the logit scale) in 668 each study. These random effects are defined by the hierarchical structure $S_s \sim N(0, \sigma)$ 669 (further detail in supplementary methods), where σ is to be estimated. The posterior 670 distribution is defined using the likelihood function,
-
- 671 $n_{i,\nu,s} \sim Bin(r_{i,\nu,s}, N_{i,\nu,s}).$ 2

672 and with the priors,

- 673 $r_{i,0,s}$ \sim Beta(1,1), 674 ! ∼ (0,10), 675 $\sigma \sim \text{Half-Cauchy}(0.25)$.
-

676 For the case-control studies, the at-risk population is not used. However, vaccine

677 effectiveness can be estimated using the odds ratio comparing the odds of vaccination in the

- 678 infection and control groups⁵⁷. Subsequently we can use the same model (Equation 1 and 2)
- 679 to fit the case-control studies (detailed in Supplementary methods).
- 680
- 681

682 **Estimating immunogenicity**

683 Our goal here is to estimate the mean vaccinia-binding titer induced by vaccination in each 684 group, as well as the spread (standard deviation) of those titers between individuals (since 685 this is important when relating antibody titers to protection³⁸). That is, we aim to estimate the 686 mean, μ_p , and standard deviation, σ_p , of the distribution of antibody titers induced in a 687 population after vaccination for a given vaccine regimen, ν . Since we do not have individual 688 level data from each study, we are limited to using only three pieces of data for each group, 689 from each study, to estimate these quantities. Specifically, the (log) GMT reported after 690 vaccination, $\bar{y}_{s,v,f,E}$, the number of individuals in these groups, $n_{s,v,f,E}$, and the standard 691 deviation of the (log) titers in these groups, $\overline{sd}_{s,v,f,E}$ (derived from the reported confidence 692 intervals, Supplementary Methods) – in each study, s, and for each vaccine group, ν 693 (accounting for different assays, E , and vaccine formulations, f). We assume that 694 individuals' (log) vaccinia-binding titers after vaccination are normally distributed, i.e.

$$
y_{i,s,\nu,f,E} \sim N(\mu_{\nu} + \mu_s + \mu_f + \mu_E, \sigma_{\nu}),
$$

696 where the mean and standard deviation of titers after vaccination with vaccine ν are μ _n and σ_{ν} (respectively), and assuming this mean is influenced by: (i) random study effects, μ_{s} (from a hierarchical model structure, where $\mu_s \sim N(0, \sigma_s)$, and σ_s , is also a parameter that is 699 inferred), (ii) a fixed effect, μ_f , to account for potential differences in antibody titers induced 700 by the two different vaccine formulations used for the MVA-BN vaccine (freeze dried and 701 liquid frozen), and (iii) a fixed effect, μ_F , to account for the effect of the different ELISA 702 assays (but the latter was not a significant covariate, and removed from further analysis). We 703 use the above model to estimate the distribution of the participant level vaccinia-binding 704 titers, using the sample mean, $\bar{y}_{s,v,f,E}$, and sample standard deviation, $\bar{sd}_{s,v,f,E}$ from each 705 group/study as 'sufficient statistics' to estimate this distribution (i.e. we require no other 706 information to estimate the participant level distribution of vaccinia-binding titers other than 707 the available sample means and standard deviations - derivation in supplementary material, 708 including likelihood function). We impose the below weakly informative priors on our 709 parameters,

710 $\mu_d \sim N(0,10)$

$$
log(\sigma_d) \sim N(0.10)
$$

$$
\mu_E \sim N(0,10)
$$

$$
\mu_f \sim N(0.10)
$$

$$
\sigma_{\rm s} \sim \text{Half-Cauchy}(0,1).
$$

715

 When antibody titers were below the limit of detection, this was handled in different ways across the different studies. Some studies had assigned values of "1" to the titers below the detection limit before calculating the GMT, whilst other studies assigned those values as half the limit of detection. For consistency in our analysis, we adjusted the GMTs from the latter studies to reflect the former approach. That is, we used the reported number of seropositive samples (those above the limit of detection) to adjust GMTs from each study such that values below the limit of detection were set to "1".

723

724 **Predicting vaccine effectiveness over time**

725 We fit a model of biphasic exponential decay to the vaccinia-binding antibody titers. This 726 model has two compartments, long (x_l) and short (x_s) lived antibody titers, which each are assumed to decay with rates $δ_1$ and $δ_5$, respectively. Thus, the total antibody titer at time, t, is 728 given by $x(t) = x_l(t) + x_s(t)$, where,

729 $x_s(t) = x_0 f e^{-\delta_s t},$

730
$$
x_l(t) = x_0(1-f)e^{-\delta_l t},
$$

731 and where x_0 is the antibody titer at $t = 0$ (which is defined as a maximum of 14 days after 732 final dose or 28 days after the first dose), and f is the fraction of the initial antibody titer that 733 is short-lived. After model comparison (Table S7), we found that the decay rates δ_l and δ_s 734 are not significantly different between dosing regimens. However, we assume the initial 735 antibody titer (x_0) and the faction short-lived, f, differs for each dosing regimen and is also 736 different for historically vaccinated groups. The log (base 10) of the model and data were 737 fitted in RStan as described above in the "Estimating immunogenicity" section. We impose 738 the weakly informative priors on the decay model parameters.

- 739 $\delta_s, \delta_l \sim N(0,1)$
- 740 $f \sim U(0.1)$

741

742 **Fitting the relationship between vaccinia binding antibody titers and protection from** 743 **Mpox**

744 To analyse the relation between antibody titers and protection we applied a model we have

745 reviously used to identify a correlate of protection for COVID-19 38 . The model assumes that

746 there is a logistic relationship between the protection, P , experienced by a group of

747 individuals with a given vaccinia-binding antibody titer, x , given by,

It is made available under a CC-BY-NC 4.0 International license.

748
$$
P(x) = \frac{1}{1 + e^{-k(x - x_{50})}},
$$

749 where, x_{50} is the 50% protective titer and k describes the steepness of the relation between

750 the antibody titer and the protection.

751 We re-parameterize this function with the substitution, $A = -k(2.5 - x_{50})$, to provide better

752 numerical stability during model fitting, in cases where the two parameters trade-off, i.e.

753
$$
P(x) = \frac{1}{1 + e^{-k(x - 2.5) - A}}
$$

754 For a given vaccinated population, we must consider the observed population distribution of

755 vaccinia-specific antibody titers (with mean μ and standard deviation σ). The average

756 protection over the distribution of titers is given by,

$$
VE = \int_{-\infty}^{\infty} P(x)N(x \mid \mu, \sigma) dx
$$

758 where $N(x|\mu, \sigma)$ denotes the probability density function of the normal distribution. The data

759 on antibody titers and effectiveness are fitted simultaneously to estimate all model parameters 760 along with associated credible intervals (Table S5). The priors used and hierarchical structure

761 (to account for inter-study variability) are also provided in Table S6.

Ethics statement

- This work was approved under the UNSW Sydney Human Research Ethics Committee
- (approval HC200242).

Conflicts of interest

- CRM is on the WHO SAGE Working Group on Smallpox and Monkeypox. The authors have
- no other competing interests to declare.
- **Funding**
- This work is supported by an NHMRC program grant GNT1149990 (to MPD), Investigator
- grants (GNT1173931 to AEG, GNT2016907 to CRM and GNT1173027 to MPD) and an
- NHMRC Centre for Research Excellence BREATHE (GNT2006595). DSK is supported by a
- University of New South Wales fellowship.
- The funders had no role in the design and conduct of the study; collection, management,
- analysis, and interpretation of the data; preparation, review, or approval of the manuscript;
- and decision to submit the manuscript for publication.
- **Data and code availability**
- Extracted data and codes for analysis will be made publicly available on GitHub upon
- publication.